



Please type a plus sign (+) inside this box → **+**

(Modified) PTO/SB/21 (6-98)
Approved for use through 09/30/2000. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>	Application Number	10/084,706	
	Filing Date	February 26, 2002	
	First Named Inventor	Rasmussen, et al	
	Group Art Unit	1647	
	Examiner Name	J. Seharaseyon	
Total Number of Pages in This Submission	4 +	Attorney Docket Number	0228us410

RECEIVED
DEC 12 2002
TECH CENTER 1600/2900

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	PTO/SB/08A-B; cited references (4); return postcard
<input checked="" type="checkbox"/> Supplemental Information Disclosure Statement	<input type="checkbox"/> Small Entity Statement	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Authorization to Charge Deposit Account Please charge Deposit Account No. 50-0990 for any additional fees associated with this paper or during the pendency of this application, including any extensions of time for consideration of the documents enclosed.	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	Remarks	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Joanne R. Petithory, Reg. No. 42,995 Maxygen, Inc.
Signature	
Date	December 6, 2002

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington D C 20231 on this date <u>Dec. 6, 2002</u>			
Typed or printed name	Julie K. Mausen		
Signature		Date	<u>Dec. 6, 2002</u>



I hereby certify that this correspondence is
being deposited with the United States
Postal Service as first class mail in an envelope addressed to:
Assistant Commissioner for Patents
Washington, D.C. 20231

On December 6, 2002

By Julie K. Mauser
Julie K. Mauser

RECEIVED

DEC 12 2002

TECH CENTER 1600/2900

Attorney Docket No. 0228us410

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Rasmussen, *et al.*

Examiner: J. Seharaseyon

Application No.: 10/084,706

Art Unit: 1647

Filed: February 26, 2002

For: NEW INTERFERON
BETA-LIKE MOLECULES

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER
37 CFR § 1.97 and §1.98

Assistant Commissioner for Patents
Washington, D.C. 20231


Sir:

The references cited on attached form PTO-SB/08 are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited information be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicants believe that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action on the merits. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 50-0990. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,


Joanne R. Petithory
Reg. No. 42,995

Maxygen, Inc.
Patent Department
515 Galveston Drive
Redwood City, CA 94063
Telephone: (650) 298-5300
Facsimile: (650) 298-5446
Customer No.: 30560

Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/084,706
Filing Date	February 26, 2002
First Named Inventor	Rasmussen, et al.
Group Art Unit	1647
Examiner Name	J. Seharaseyon
Attorney Docket Number	0228us410

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			

RECEIVED

DEC 12 2002

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
	1	EP	0 287 075	B2	Dr. Rentschler Biotechnologie GmbH	10/19/1988		X
	2	EP	0 287 075 (English language translation of document AY)	B2	Dr. Rentschler Biotechnologie GmbH	10/19/1988		
	3	WO	01/15736	A2	Maxygen ApS	03/08/2001		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
	4	O'CONNELL, et al., "The Influence of Flanking Sequences on O-Glycosylation", <i>Biochemical and Biophysical Research Communications</i> , 1991, pp. 1024-1030, 180:2.	

Examiner
Signature

Date
Considered

*EXAMINER Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.